Заключение
С 1920-х гг. и по настоящее время непрерывно идет процесс совершенствования процесса лечения СД1. Разрабатываются более очищенные инсулины, модифицируются шприц-ручки, инсулиновые помпы и средства для самоконтроля. Прогресс в области фармакокинетики и фармакодинамики аналогов инсулина, а также способов доставки инсулина позволил разнообразить варианты заместительной инсулинотерапии, чтобы максимально приблизить ее к режиму физиологической секреции эндогенного инсулина. Появление цифровых технологий позволило сделать процесс лечения и самоконтроля СД более удобным как для пациента, так и для врача. Тем не менее, несмотря на все это, СД1 до сих пор остается одним из сложно контролируемых заболеваний, требующих постоянного наблюдения со стороны пациента. Развитие таких отраслей медицинской науки, как трансплантология и биоинженерия, представляется актуальным и, вероятно, в будущем поможет более эффективно бороться с СД1.
Литература
1. Плаксин Н.С., Куприянова В.М., Богданова Т.М. Сахарный диабет: история открытия, осложнения, распространенность // Международный студенческий научный вестник. 2018. № 5. URL: https://eduherald.ru/ru/article/view?id=19223 (дата обращения 05.05.2023).
2. URL: https://sd.diaregistry.ru/
3. Jabbour G., Henderson M., Mathieu M.E. Barriers to active lifestyles in children with type 1 diabetes // Can. J. Diabetes. 2016. Vol. 40, N 2. P. 170-172.
4. Van Name M.A., Hilliard M.E., Boyle C.T. et al. Nighttime is the worst time: parental fear of hypoglycemia in young children with type 1 diabetes // Pediatr. Diabetes. 2018. Vol. 19, N 1. P. 114-120.
5. Foster N.C., Beck R.W., Miller K.M. et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018 // Diabetes Technol. Ther. 2019. Vol. 21, N 2. P. 66-72.
6. Pettus J.H., Zhou F.L., Shepherd L. et al. Incidences of severe hypoglycemia and diabetic ketoacidosis and prevalence of microvascular complications stratified by age and glycemic control in U.S. Adult patients with type 1 diabetes: a real-world study // Diabetes Care. 2019. Vol. 42, N 12. P. 2220-2227.
7. Аметов А.С., Пуговкина Я.В., Вовк П.С. Инсулинотерапия - история успеха длиной в век. Фокус на базальный инсулин // Эндокринология: новости, мнения, обучение. 2021. Т. 10, № 1. C. 26-33.
8. Goeddel D.V., Kleid D.G., Bolivar F., Heyneker H.L., Yansura D.G., Crea R. et al. Expression in Escherichia coli of chemically synthesized genes for human insulin // Proc. Natl Acad. Sci. USA. 1979. Vol. 76. P. 106-110.
9. Miller W.L., Baxter J.D. Recombinant DNA - a new source of insulin // Diabetologia. 1980. Vol. 18. P. 431-436.
10. Cereghino G.P.L., Cregg J.M. Applications of yeast in biotechnology: protein production and genetic analysis // Curr. Opin. Biotechnol. 1999. Vol. 10. P. 422-427.
11. Окминян Г.Ф., Латышев О.Ю., Киселева Е.В., Касаткина Э.П., Самсонова Л.Н. Эволюция препаратов базального инсулина: от простого к сложному // Эндокринология: новости, мнения, обучение. 2021. Т. 10, № 1. C. 18-25.
12. Hirsch I.B., Juneja R., Beals J.M., Antalis C.J., Wright E.E. The Evolution of insulin and how it informs therapy and treatment choices // Endocr. Rev. 2020. Vol. 41, N 5. P. 733-755.
13. Pettus J., Santos Cavaiola T., Tamborlane W.V., Edelman S. The past, present, and future of basal insulins // Diabetes Metab. Res. Rev. 2016. Vol. 32, N 6. P. 478-496.
14. Home P. The evolution of insulin therapy // Diabetes Res. Clin. Pract. 2021. Vol. 175. Article ID 108816.
15. Klonoff D.C., Aimbe F., Kerr D. Smart pens will improve insulin therapy // J. Diabetes Sci. Technol. 2018. Vol. 12, N 3. P. 551-553.
16. Gomez-Peralta F., Abreu C., Gomez-Rodriguez S. et al. A novel insulin delivery optimization and tracking system // Diabetes Technol. Ther. 2019. Vol. 21, N 4. P. 209-214.
17. Laffel L.M., Limbert C., Phelan H. et al. ISPAD clinical practice consensus guidelines 2018: Sick day management in children and adolescents with diabetes // Pediatr. Diabetes. 2018. Vol. 19, suppl. 27. P. 193-204.
18. Zaharieva D.P., McGaugh S., Pooni R., Vienneau T., Ly T., Riddell M.C. Improved open-loop glucose control with basal insulin reduction 90 minutes before aerobic exercise in patients with type 1 diabetes on continuous subcutaneous insulin infusion // Diabetes Care. 2019. Vol. 42, N 5. P. 824-831.
19. Pozzilli P., Battelino T., Danne T. et al. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics // Diabetes Metab. Res. Rev. 2016. Vol. 32, N 1. P. 21-39.
20. Misso M.L., Egberts K.J., Page M., O’Connor D., Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus // Cochrane Database Syst. Rev. 2010. Vol. 20, N 1. Article ID CD 005103.
21. Karges B., Schwandt A., Heidtmann B. et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes // JAMA. 2017. Vol. 318, N 14. P. 1358-1366.
22. Bollyky J.B., Bravata D., Yang J., Williamson M., Schneider J. Remote lifestyle coaching plus a connected glucose meter with certified diabetes educator support improves glucose and weight loss for people with type 2 diabetes // J. Diabetes Res. 2018. Vol. 2018. Article ID 3961730.
23. Christiansen M., Greene C., Pardo S. et al. A new, wireless-enabled blood glucose monitoring system that links to a smart mobile device: accuracy and user performance evaluation // J. Diabetes Sci. Technol. 2017. Vol. 11, N 3. P. 567-573.
24. Deiss D., Bolinder J., Riveline J.P. et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring // Diabetes Care. 2009. Vol. 29, N 12. P. 2730-2732.
25. Langendam M., Luijf Y.M., Hooft L., Devries J.H., Mudde A.H., Scholten R.J. Continuous glucose monitoring systems for type 1 diabetes mellitus // Cochrane Database Syst. Rev. 2012. Vol. 1, N 1. CD 008101.
26. Piona C., Dovc K., Mutlu G.Y. et al. Non-adjunctive flash glucose monitoring system use during summer-camp in children with type 1 diabetes: the free-summer study // Pediatr. Diabetes. 2018. Vol. 19, N 7. P. 1285-1293.
27. Deiss D., Irace C., Carlson G., Tweden K.S., Kaufman F.R. Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: a post-market registry study // Diabetes Technol. Ther. 2020. Vol. 22, N 1. P. 48-52.
28. Zaharieva D.P., Turksoy K., McGaugh S.M. et al. Lag time remains with newer real-time continuous glucose monitoring technology during aerobic exercise in adults living with type 1 diabetes // Diabetes Technol. Ther. 2019. Vol. 21, N 6. P. 313-321.
29. DeSalvo D.J., Miller K.M., Hermann J.M. et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: international comparison from the T1D Exchange and DPV Initiative // Pediatr. Diabetes. 2018. Vol. 19, N 7. P. 1271-1275.
30. Dovc K., Cargnelutti K., Sturm A., Selb J., Bratina N., Battelino T. Continuous glucose monitoring use and glucose variability in pre-school children with type 1 diabetes // Diabetes Res. Clin. Pract. 2019. Vol. 147. P. 76-80.
31. Bergenstal R.M. Continuous glucose monitoring: transforming diabetes management step by step // Lancet. 2018. Vol. 391, N 10 128. P. 1334-1336.
32. Kropff J., Choudhary P., Neupane S. et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial // Diabetes Care. 2017. Vol. 40, N 1. P. 63-68.
33. Polonsky W.H., Hessler D., Ruedy K.J. et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial // Diabetes Care. 2017. Vol. 40, N 6. P. 736-741.
34. Nimri R., Ochs A.R., Pinsker J.E. et al. Decision support systems and closed loop // Diabetes Technol. Ther. 2019. Vol. 21, N S 1. P. S 42-S 56.
35. Shapiro A.M.J., Lakey J.R.T., Ryan E.A. et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen // N. Engl. J. Med. 2000. Vol. 343, N 4. P. 230-238.
36. Docherty F.M., Sussel L. Islet regeneration: endogenous and exogenous approaches // Int. J. Mol. Sci. 2021. Vol. 22, N 7. Article ID 3306.
37. Yang J., Liu H., Sun H., Wang Z., Zhang R., Liu Y. et al. construction of induced pluripotent stem cell line (ZZUi0017-A) from the fibroblast cells of a female patient with CACNA1A mutation by unintegrated reprogramming approach // Stem Cell Res. 2020. Vol. 48. Article ID 101946.
38. Wobus A.M., Boheler K.R. Embryonic stem cells: prospects for developmental biology and cell therapy // Physiol. Rev. 2005. Vol. 85, N 2. P. 635-678.
39. Klimanskaya I., Chung Y., Becker S., Lu S.J., Lanza R. Human embryonic stem cell lines derived from single blastomeres // Nature. 2006. Vol. 444, N 7118. P. 481-485.
40. Baylis F. Human embryonic stem cell lines: the ethics of derivation // J. Obstet. Gynaecol. Can. 2002. Vol. 24, N 2. P. 159-163.
41. Hovatta O., Stojkovic M., Nogueira M., Varela-Nieto I. European scientific, ethical, and legal issues on human stem cell research and regenerative medicine // Stem Cells. 2010. Vol. 28, N 6. P. 1005-1007.
42. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyvk A.F., Keiliss-Borok I.V. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues: cloning in vitro and retransplantation in vivo // Transplantation. 1974. Vol. 17, N 4. P. 331-340.
43. Sousa B.R., Parreira R.C., Fonseca E.A., Amaya M.J., Tonelli F.M.P., Lacerda S.M.S.N. et al. Human adult stem cells from diverse origins: an overview from multiparametric immunophenotyping to clinical applications // Cytometry A. 2014. Vol. 85, N 1. P. 43-77.
44. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J. et al. Multilineage cells from human adipose tissue: implications for cell-based therapies // Tissue Eng. 2001. Vol. 7, N 2. P. 211-228.
45. Prabakar K.R., Domínguez-Bendala J., Damaris Molano R., Pileggi A., Villate S., Ricordi C. et al. Generation of glucose-responsive, insulin-producing cells from human umbilical cord blood-derived mesenchymal stem cells // Cell Transplant. 2012. Vol. 21, N 6. P. 1321-1339.
46. Shivakumar S.B., Lee H.J., Son Y.B., Bharti D., Ock S.A., Lee S.L. et al. In vitro differentiation of single donor derived human dental mesenchymal stem cells into pancreatic β cell-like cells // Biosci. Rep. 2019. Vol. 39, N 5. Article ID BSR 20182051.
47. Kanafi M.M., Rajeshwari Y.B., Gupta S., Dadheech N., Nair P.D., Gupta P.K. et al. Transplantation of islet-like cell clusters derived from human dental pulp stem cells restores normoglycemia in diabetic mice // Cytotherapy. 2013. Vol. 15, N 10. P. 1228-1236.
48. Guo Q.S., Zhu M.Y., Wang L., Fan X.J., Lu Y.H., Wang Z.W. et al. Combined transfection of the three transcriptional factors, PDX-1, NeuroD 1, and MafA, causes differentiation of bone marrow mesenchymal stem cells into insulin-producing cells // Exp. Diabetes Res. 2012. Vol. 2012. Article ID 672013.
49. Lechner A., Yang Y.-G., Blacken R.A., Wang L., Nolan A.L., Habener J.F. No evidence for significant transdifferentiation of bone marrow into pancreatic-cells in vivo // Diabetes. 2004. Vol. 53, N 3. P. 616-623.
50. Choi J.B., Uchino H., Azuma K., Iwashita N., Tanaka Y., Mochizuki H. et al. Little evidence of transdifferentiation of bone marrow-derived cells into pancreatic beta cells // Diabetologia. 2003. Vol. 46, N 10. P. 1366-1374.
51. Ezquer F., Ezquer M., Contador D., Ricca M., Simon V., Conget P. The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment // Stem Cells. 2012. Vol. 30, N 8. P. 1664-1674.
52. Dave S.D., Vanikar A.V., Trivedi H.L., Thakkar U.G., Gopal S.C., Chandra T. Novel therapy for insulin-dependent diabetes mellitus: infusion of in vitro-generated insulin-secreting cells // Clin. Exp. Med. 2015. Vol. 15, N 1. P. 41-45.
53. Thakkar U.G., Trivedi H.L., Vanikar A.V., Dave S.D. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus // Cytotherapy. 2015. Vol. 17, N 7. P. 940-947.
54. Intravenous infusion of human adipose tissue-derived mesenchymal stem cells to treat type 1 diabetic mellitus in mice: an evaluation of grafted cell doses // Adv. Exp. Med. Biol. 2018. Vol. 1083. P. 145-156.
55. Li L., Hui H., Jia X., Zhang J., Liu Y., Xu Q., Zhu D. Infusion with human bone marrow-derived mesenchymal stem cells improves β-cell function in patients and non-obese mice with severe diabetes // Sci. Rep. 2016. Vol. 6. Article ID 37894.
56. Yaochite J.N.U., Caliari-Oliveira C., de Souza L.E.B., Neto L.S., Palma P.V.B., Covas D.T. et al. Therapeutic efficacy and biodistribution of allogeneic mesenchymal stem cells delivered by intrasplenic and intrapancreatic routes in streptozotocin-induced diabetic mice // Stem Cell Res. Ther. 2015. Vol. 6, N 1. P. 31.
57. Chen J., Chen J., Cheng Y., Fu Y., Zhao H., Tang M. et al. Mesenchymal stem cell-derived exosomes protect beta cells against hypoxia-induced apoptosis via MiR-21 by alleviating ER stress and inhibiting P38 MAPK phosphorylation // Stem Cell Res. Ther. 2020. Vol. 11, N 1. P. 97.
58. Mesples A., Majeed N., Zhang Y., Xiang H. Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: preliminary results // Med. Sci. Monit. 2013. Vol. 19. P. 852-857.
59. Carlsson P.O., Schwarcz E., Korsgren O., le Blanc K. Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells // Diabetes. 2015. Vol. 64, N 2. P. 587-592.
60. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors // Cell. 2006. Vol. 126, N 4. P. 663-676.
61. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors // Cell. 2007. Vol. 131, N 5. P. 861-872.
62. Okit K., Yamakawa T., Matsumura Y., Sato Y., Amano N., Watanabe A. et al. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells // Stem Cells. 2013. Vol. 31, N 3. P. 458-466.
63. Xue Y., Cai X., Wang L., Liao B., Zhang H., Shan Y. et al. Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells // PLoS One. 2013. Vol. 8, N 8. Article ID e70573.
64. Moede T., Leibiger I.B., Berggren P.O. Alpha cell regulation of beta cell function // Diabetologia. 2020. Vol. 63, N 10. P. 2064-2075.
65. Adams M.T., Gilbert J.M., Hinojosa Paiz J., Bowman F.M., Blum B. Endocrine cell type sorting and mature architecture in the islets of langerhans require expression of roundabout receptors in β cells // Sci. Rep. 2018. Vol. 8, N 1. Article ID 10876.
66. Caicedo A. Paracrine and autocrine interactions in the human islet: more than meets the eye // Semin. Cell Dev. Biol. 2013. Vol. 24, N 1. P. 11-21.
67. URL: https://habr.com/ru/post/445020/